Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 January 2021 | Story Lacea Loader
Ivermectin

FARMOVS, a wholly owned clinical research company of the University of the Free State (UFS), together with several medical and scientific experts at the university, is currently in the process of preparing a clinical trial protocol to determine the efficacy of Ivermectin for COVID-19 in a randomised, controlled study according to the requirements of the legal professions, in order to submit it for approval to the relevant national regulatory authority.

FARMOVS is a South African specialty full-service clinical research organisation conducting ICH-GCP-compliant Phase I to IV clinical trials. FARMOVS’ competitive advantage is its wealth of bioequivalence and Phase I experience and expertise, patient recruitment success, and a clinical research facility with the only onsite ISO (International Organization for Standardization) and GLP (Good Laboratory Practice) certified bioanalytical laboratory on the African continent.

By participating in the preparation of the clinical trial protocol, FARMOVS and the UFS remain supportive of and committed to contributing to the development of treatments and treatment strategies to battle the COVID-19 pandemic. Should the clinical trial protocol be approved by the relevant national regulatory authority, the UFS will be the first university in South Africa to attempt such a study.

The university management is aware of a WhatsApp voice clip being circulated, in which reference is made to a particular meeting, and mention is made of the role the institution is playing in establishing the efficacy of Ivermectin for COVID-19. The voice clip is premature and was shared with a small group, from where it went viral. The voice clip is also not factual – specifically regarding the university and its alleged opinion pertaining to the usage and need for scientific investigation into the matter.  

The UFS is committed to rigorous science and evidence-based research, and both FARMOVS and the university fully support the published opinions and guidelines of the South African Health Products Regulatory Authority (SAHPRA) and the scientific advisory boards established by the scientific community, as well as the stance of the South African government on Ivermectin for COVID-19.

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

First-year students encouraged to attend UFS welcoming function
2005-01-12

The University of the Free State (UFS) will host a welcoming function for all new first-year students and their parents on Saturday 15 January 2005 in the Callie Human Centre on the main campus in Bloemfontein.

The function starts at 11.00 and will be addressed by the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie. UFS staff will also be available to provide vital information to first-year students on academic matters.

According to UFS Registrar, Mr Vernon Collett, Saturday’s welcoming function can assist students and parents by providing vital information on the many high quality academic learning programmes on offer at the UFS in six faculties.

“If students and parents have this information it will make the registration process which starts next week Monday 17 January much smoother,” Mr Collett said.

The UFS has split the registration process into various categories of students and Mr Collett appealed to all students to adhere to the dates and times which apply to them as a one-stop service will be available so as to avoid unnecessary delays in the registration process.

The registration of first-time entering first-year students who applied before 30 November 2004 to study at the Bloemfontein campus will take place from Monday 17 January 2005 to 21 January 2005 at the Callie Human Centre.

Senior undergraduate students (that is, students entering their second or later year of study) may register from 22 to 29 January 2005.

Postgraduate students, first time entering first year students and other students who applied for admission to the main campus after 30 November 2004 must register at the Callie Human from 31 January 2005 to 4 February 2005.

Due to the limitations placed by government on student numbers, the applications of students who applied late will be regarded as pending and will be processed as places became available.

Vista campus

The Vista campus in Bloemfontein – which was incorporated into the UFS in January 2004 – no longer accepts applications from first-year students. Such prospective students had to apply to the UFS main campus.

Students who had been registered as Vista students last year must register at the Vista campus on the same dates as applicable on the main campus.

Qwaqwa Campus

At the Qwaqwa campus of the UFS, all first-time entering first-year students must report on 17 January 2005, after which the registration of these students will take place according to a specific programme.

The official welcoming functioning for new first-years at the Qwaqwa campus of the UFS will take place on Saturday 22 January 2005 at 11am in the Rolihlahla Mandela Hall on the Qwaqwa campus. As on the main campus, this function will also be addressed by the Rector and Vice-Chancellor, Prof Fourie.

Mr Collett appealed to first-year students who have applied to study at the Qwaqwa campus and their parents to attend this function which fulfills the same role as the one held on the Bloemfontein campus.

Detailed information on the dates and times of registration for the various faculties and academic learning programmes is available on the UFS website: http://www.uovs.ac.za/content.php?cid=9

Prospective students may also call 051-401-3000 for more information.

    Media release
Issued by: Anton Fisher
Media Representative
Cell: 072-207-8334

 


12 January 2005

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept